Effect of Budesonide Inhalation on Asthmatic Child: A Randomized Controlled Trial

Abstract

Background: Asthma is a diverse inflammatory airway illness characterized by intermittent respiratory manifestations, and inhaled steroids (ICS) constitute the foundation of all asthma management regimens. The aim of this study was to examine the therapeutic efficacy of inhaled Budesonide (BUD) regimens for recurrent wheeze treatment in pre-schoolers. Methods: This retrospective randomized controlled research involved 70 pediatric subjects aged from 6-12 years old, both sexes having four wheezing episodes or more in the last year; and satisfying at least one main condition or two minor of them. Case selection was rigorously regulated by experts who specialize in children’s respiratory disorders diagnosis and treatment, notably asthma. The included children had mild-to-moderate asthma. Results: After treatment, FEV1, FVC and FEV1: FVC were significantly elevated in group A than group B (P value <0.001). Urgent care visits and hospitalizations because of asthma were significantly lower in group A than group B (P value = 0.003 and 0.008 respectively). Conclusions: We have shown that the BUD Inhalation is an effective and safe management for long term asthma treatment. Compared to placebo, BUD was related with a higher decrease in asthma manifestations and a rise in the number episode free days.